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Abstract: The recreational use of androgenic anabolic steroids (AAS) has been associated with a range of health and 
psychological problems in the past, but very little research has considered what impact AAS might have upon cognition 
and memory. The present study aimed to identify whether the recreational use of AAS is linked to deficits in everyday 
retrospective memory (RM) and everyday prospective memory (PM). We assessed self-reports of RM and PM in 25 
regular AAS users and 28 Non-Users (all were males, regular gym users and aged between 18-30 years) using the 
Prospective and Retrospective Memory Questionnaire. A Recreational Drug Use Questionnaire was used to measure AAS 
use and alcohol use. The Hospital Anxiety and Depression Scale measuredtwo dimensions of mood (anxiety and 
depression). The results revealed thatrecreational AAS users reported significantly more everyday RM lapses (AAS Mean 
= 2.41 vs Non-Users Mean = 1.66; p<0.001)and significantly more everyday PM lapses (AAS Mean = 2.79 vs Non-User 
Mean = 1.84; p<0.001) than the Non-User group. These findings were not attributable to other substance use or mood 
variations. This is the first study to demonstrate everyday memory deficits associated with AAS use and it is suggested 
that such deficits be added to the growing list of health and cognitive problems associated with AAS use. 
Keywords: Androgenic anabolic steroids, everyday memory, prospective memory, retrospective memory. 
INTRODUCTION 
 Androgenic anabolic steroids (AAS) are a group of 
synthetically produced variants of the male sex hormone 
testosterone. They have traditionally been used clinically to 
treat a range of medical conditions, such as delayed puberty, 
loss of lean muscle mass, cancer and AIDS, but more 
recently have been used in a recreational sporting context to 
promote fat reduction and muscle building. Since the 1980s 
many millions of individuals worldwide have used AAS in a 
sporting context in order to promote muscle growth and 
improve athletic performance, with recent figures of AAS 
prevalence rates amongst gym users as high as 38% and a 
clear preponderance of male users [1-3]. Since the onset of 
recreational AAS use, research has shown that persistent use 
of such drugs is now associated with a number of health and 
psychiatric complications. 
 A myriad of health and psychiatric complications have 
been associated with the recreational use of AAS. For 
example, somatic complications such as physical skin lesions 
(including acne and abscesses), edema (swelling due to 
excess fluid being trapped, typically in the extremities of the 
body), and more severe symptoms including cardiac 
palpitations, long-term cardiovascular diseases (including 
cardiac dysrhythmia, myocardial infarction and pulmonary 
embolism), decreased fertility and sexual dysfunction [4-9]. 
In terms of psychiatric symptoms, AAS use has been 
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associated with increased levels of aggression, including in 
some severe cases, increased hostility, antisocial and violent 
behaviour towards others – sometimes also referred to as 
“Roid Rage” [10-13]. AAS use has also been linked to 
severe mental disorders, including mania, depression, 
suicidality, psychoses and may be addictive [14-19]. 
However, it should be noted that the degree to which AAS 
users are at risk of such complications is dependent upon a 
range of factors, such as length of AAS use, dose, and the 
use of other drugs alongside AAS, for example excessive 
drinking can exacerbate such problems and act as a confound 
on the results. 
 Only a handful of studies to date have considered what 
effect recreational AAS use has on cognition, including 
memory function. In one study [20] 44 male non-users aged 
between 29-55 years were compared with a comparison 
group of 31 male participants who had used AAS in a 
recreational context for an average of seven years. Each 
participant was asked to complete five cognitive tests that 
assessed a wide range of cognitive functions: memory for 
shapes and locations of objects, memory for lists of words, 
reaction time, sustained attention, and speed of information 
processing. Results revealed that long-term AAS users 
performed significantly worse than non-users on visuospatial 
memory (the Pattern Recognition Memory test), with no 
differences detected on any of the other cognitive tests. 
Performance scores on the visuospatial memory task 
declined noticeably with increasing lifetime AAS dose and 
this finding remained stable after controlling for potential 
confounding factors, such as other substance use, indicating 
that the findings were likely to be attributable to AAS use. In 
a more recent study, 22 adult male AAS users were 
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administered 4 computerized tests from the Cambridge 
Neuropsychological Test Automated Battery and the Iowa 
Gambling Task. Subsample analyses indicated that on-cycle 
users (those who used AAS with interspersed periods of 
abstinence) had reduced performance on cognitive measures 
of inhibitory control and attention, with no reduction in 
performance evident on tests of planning or decision making 
[21]. Taken together these findings suggest there may be 
selective cognitive deficits associated with persistent AAS 
use. 
 The deficits observed in the two previous studies [20, 21] 
are all examples of retrospective memory (RM) – which 
refers to the recall of information for people, words, numbers 
and events encountered or experienced in the past [22]. The 
first aim of the current study was therefore to assess whether 
AAS use impedes RM within an everyday context, beyond 
the laboratory based context used in the two previously 
published studies. The second aim of the current study was 
to extend our understanding of putative everyday memory 
deficits associated with AAS use by assessing everyday 
prospective memory (PM) – which refers to remembering a 
planned intention and action at an appropriate time in the 
future [22]. RM is thought to play a major role in prospective 
remembering [23], for example, RM helps to store the 
intended PM plan prior to its enactment and helps retrieve 
the content of the intention when the time for initiating the 
plan is reached. Therefore, since both RM and PM are 
intimately related, any deficits in RM associated with AAS 
use should be accompanied by deficits in PM. The overall 
objective of the current study was to assess putative deficits 
in everyday RM and PM associated with AAS use when 
compared with a Non-User comparison group. The 
Prospective and Retrospective Memory Questionnaire 
(PRMQ) [24] was used to measure self-reported everyday 
RM and PM lapses within an everyday context. The 
following hypothesis was tested: if regular use of AAS does 
compromise everyday memory then it is expected that the 
AAS user group should report more deficits in terms of RM 
and PM, when compared to a non-user group. 
MATERIALS AND METHODOLOGY 
Design and Setting 
 This study was conducted using a non-experimental 
design and was questionnaire based. Ethical clearance was 
granted by the School of Life Sciences at Northumbria 
University. Participation was voluntary and each participant 
was tested individually for approximately 15 minutes on 
campus. 
Participants 
 An original sample of 300 undergraduate students 
studying at university in the North East of England was 
canvassed as a part of a general (unpublished) project on 
students’ recreational drug use, mood and everyday memory. 
From this data base a group of AAS users and a comparison 
group of Non-Users were selected for the current study. The 
following exclusion criteria were used to determine the final 
sample included in the current study.1. Given that females 
rarely use AAS and that the majority of research on AAS use 
is based on male users [1], the current study focused on 
males only to reflect this pattern. 2. Since other drug use 
(such as excessive drinking, cannabis and ecstasy) have been 
linked to memory deficits independent of AAS use [25-27] 
anyone who reported having used one or more of these 
substances/drinking excessively was excluded from the final 
sample. 3. Anyone who reported using alcohol within the 
last 48 hours was also excluded in order to control for 
possible ‘hangover’ effects. 4. Anyone who reported having 
suffered/was currently suffering from a psychiatric condition 
(e.g. substance-dependence, clinical depression or amnesia) 
which might affect cognition independent of AAS use was 
also excluded from the final sample. 5. Finally, only 
participants aged between 18-30 years were included in the 
final sample in order to reduce any age-related memory 
effects. Given that mood has been known to affect everyday 
memory regardless of drug use [28, 29] this was analysed 
and compared between the two groups. Normal (non-
excessive) alcohol use per week, last alcohol use in hours 
and the number of years spent drinking alcohol were also 
analysed and compared between the two groups. Based on 
these exclusion criteria, the original sample of 300 
participants canvassed was reduced to 53, within which 25 
were regular recreational AAS users and 28 were Non-Users. 
All were male, aged between 18-30 years and all were 
regular gym users. The AAS user group had a mean age of 
23.8 (SD = 2.97), used AAS on average 2 times per week 
(SD = 0.57), with an average dose of 149 mg per occasion 
(SD = 132) and had last used AAS an average of 4.2 days 
prior to participation (SD = 5.76). The 28 who did not use 
AAS made up the Non-User group (Mean age = 22.3 (SD = 
2.41)). All participants were unpaid volunteers who 
consented to participation and were debriefed. 
Measures and Procedure 
 RM and PM were assessed using the Prospective and 
Retrospective Memory Questionnaire (PRMQ) which is a 
standardised self-report measure developed by previous 
researchers [24]. The PRMQ assesses self-reported RM and 
PM slips in everyday life and shows high internal 
consistency, with the reliability on Cronbach’s alpha being 
0.89. On the PRMQ, 8 items pertain to RM (e.g., “Do you 
repeat the same story to the same person on different 
occasions?”) and 8 items pertain to PM (e.g., “Do you 
decide to do something in a few minutes’ time and then 
forget to do it?”). Each participant rated how often they 
experienced such failures on a 5-point scale from "very often" 
(5) to "never" (1) by circling the response that best reflects their 
memory ability. A mean score for RM slips/failures was 
calculated, along with a mean score for PM slips/failures. A 
mean score for each scale (the RM and PM scales) was 
calculated by totalling the sum of scores on each scale and 
dividing this by the number of questions (8), with a higher 
score in both cases indicating more memory slips/failures. A 
modified version of a Recreational Drug Use 
Questionnaire (RDUQ) used in previous research [25-27] 
was used here to measure AAS use and alcohol indices – 
i.e. the number of units of alcohol used per week, when 
alcohol was last used in hours and the number of years 
spent drinking alcohol. [Since anyone who smoked, used 
an illegal substance (e.g. cannabis or ecstasy), drank 
excessively or had drunk alcohol within the past 48-hours, 
or had reported a psychiatric illness, was excluded prior to 
the study, these questions were omitted for the final 53 
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participants]. The Hospital Anxiety and Depression Scale 
(HADS) measured mood in terms of levels of anxiety and 
depression. HADS is a 14-item standardised self-report 
questionnaire; 7 items of which measured generalised 
anxiety symptoms and 7 generalised depressive symptoms; 
with the higher score indicating a greater frequency of 
anxiety or depression symptoms. The HADS has been shown 
to be a valid and reliable measure of mood in non-clinical 
samples [30]. All measures were collected by self-reports 
and no biological measures were taken. Each participant was 
tested individually and in a quiet location at the university. 
The order of presentation remained constant across 
participants, with the PRMQ administered first, and followed 
by the RDUQ and finally the HADS. 
Data Analysis and Statistical Methods 
 All data was entered into SPSS-21. Since Shapiro-
Wilk tests for normality revealed that the data for the self-
reported RM and PM scores from PRMQ, thenumber of 
years spent drinking alcohol, last alcohol use in hours, 
HADS anxiety scores and HADS depression scores were not 
normally distributed, non-parametric Mann-Whitney U tests 
were performed on this data. Finally, since the Shapiro-
Wilk tests for normality revealed the data for the number of 
units of alcohol consumed per week was normally 
distributed across the two groups, an independent t-test was 
applied to this data. 
RESULTS 
 Table 1 below contains the mean scores and standard 
deviations (in brackets) comparing the AAS users with the 
Non-Users on the number of alcohol units consumed per 
week, the number of years spent drinking alcohol, last 
alcohol use in hours, HADS anxiety scores, HADS 
depression scores, and the mean scores for the RM and PM 
subscales of the PRMQ. Non-parametric Mann-Whitney U 
tests were performed to ascertain the presence of any 
significant differences between the AAS users and Non-
Users. These tests revealed that AAS users reported 
significantly more self-reported failures in RM  
(U = 179.50, p<0.005) and PM (U = 163.50, p<0.001) 
when compared with the Non-Users. Mann-Whitney U 
tests revealed no significant differences between the AAS  
 
Table 1. Descriptive data across AAS users AND Non-users. 
 
 AAS Users (N = 25) 
Non-Users (N = 
28) 
Alcohol Units Per week 22.3 (2.25) 17.2 (7.64) 
Years Drinking Alcohol 7.00 (1.26) 7.05 (5.28) 
Last Alcohol Use in 
Hours 76.0 (18.0) 88.0 (161) 
HADS Anxiety 3.76 (1.94) 2.89 (2.67) 
HADS Depression 7.44 (3.58) 7.75 (4.52) 
RM*  2.41 (0.81) 1.66 (0.55) 
PM* 2.79 (1.09) 1.84 (0.47) 
Means and standard deviations (in brackets) comparing the AAS users with the Non-
Users on the number of alcohol units consumed per week, the number of years spent 
drinking alcohol, their last alcohol use in hours, HADS anxiety scores, HADS 
depression scores, and the RM and PM mean scores from the PRMQ. An asterisk 
indicates a significant between-group difference at p < 0.005 or below. 
users and Non-Users in terms of years spent drinking 
alcohol (U = 45.50, p = 0.47), last alcohol use in hours  
(U = 31.00, p = 0.10), HADS anxiety (U = 243, p = 
0.054), or HADS depression scores (U = 308.00, p = 
0.46). Finally, an independent t-test revealed no significant 
difference between the two groups in terms of the number of 
units of alcohol consumed per week (t(22) = 21.88, p = 
0.07). 
DISCUSSION 
 The present study compared the recreational use of AAS 
in a sports context, comparing two groups of regular gym 
users –a group of AAS users and a Non-User comparison 
group on everyday RM and PM lapses. From a large sample 
size of 300 questioned originally about their general drug 
use, mood and everyday memory; after omitting anyone who 
reported drinking excessively or reported using alcohol 
within the past 24 hours, those who smoked, those who used 
illicit drugs, or those who suffered from a psychiatric 
disorder, the present study compared 25 regular recreational 
AAS users and 28 Non-Users, all of whom were regular gym 
users and male. The results from this sample revealed that 
the AAS user group reported significantly more RM and PM 
lapses in an everyday context compared with the Non-User 
group. The two groups did not differ significantly in terms of 
weekly (moderate) alcohol use, the total number of years 
spent drinking alcohol, last alcohol use in hours, or mood. 
Therefore the findings cannot be attributable to potentially 
confounding factors such as other drug use [25-27] or mood 
[28-30] known to affect memory independently. The finding 
that the recreational use of AAS leads to everyday memory 
problems, specifically RM and PM deficits, is generally 
consistent with previous work that has shown cognitive/ 
memory deficits associated with AAS use and it is suggested 
that RM and PM deficits be added to the growing list of 
cognitive deficits associated with AAS use. The finding that 
AAS use impedes everyday RM suggests that the memory 
deficits experienced by AAS users extends beyond the 
laboratory based context found in the two previously 
published pieces of research [20, 21]. The second finding 
that AAS use impedes PM extends our understanding further 
by suggesting users also have problems when it comes to 
planning for future actions. To our knowledge this analysis is 
the first study that has looked at AAS use within an everyday 
memory context and may be important due to the critical role 
RM and PM play in everyday independent living [31]. 
 Given the scarcity of research into the cognitive deficits 
associated with AAS use, it is not surprising that relatively 
little is known about the exact mechanisms that may 
underpin the cognitive deficits found in previous studies. 
However, recent animal research [32] has provided evidence 
that supra-physiological doses of AAS can cause neurotropic 
unbalance and related behavioural disturbances in Nerve 
Growth Factor (NGF) levels and NGF receptor expression in 
the hippocampus and in the basal forebrain of the rats 
exposed to high doses of AAS. NGF mediates higher brain 
functions such as learning and memory and the findings 
from this work raises the concern that persistent AAS use in 
humans may affect those mechanisms that lie at the core of 
neuronal plasticity (the brain's ability to reorganize itself by 
forming new neural connections across a person’s life-span). 
Given the importance of the basal forebrain in producing 
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acetylcholine which plays a key role in the ability of brain 
cells to transmit information to one another [33] and the role 
the hippocampus plays in memory consolidation [34], it is 
feasible that the memory deficits observed in previous work 
and in the current study may reflect damage caused to brain 
plasticity in humans who use AAS. However, further work 
on the potential interaction between persistent AAS use, 
brain plasticity and memory deficits in human populations is 
clearly needed before any firm conclusions can be reached. 
Taking into account the data from previous studies about the 
health, psychiatric and cognitive problems associated with 
AAS use, it is striking that despite these being widely 
publicised individuals continue to use the drug. It is 
important to attempt to ascertain why this might be the case 
and attempt to understand users’ motivations. A more 
detailed examination using qualitative methods or open-
ended questions may provide us with some insight into AAS 
users’ perceptions of the benefits of use outweighing the 
costs [35]. Such an approach might also provide insights into 
whether they are aware of what impact AAS use has upon 
everyday cognition. 
LIMITATIONS AND FUTURE DIRECTIONS 
 The present study is limited in a number of ways and 
these factors need to be considered when interpreting the 
findings reported here. First the sample mainly consists of 
students and it is likely that students will be of above 
average intelligence and well educated. It is therefore 
important to determine whether the same effects are found 
with wider populations within society. The reliability and 
validity of the verbal reports of drug use provided by 
participants could be explored further in future studies based 
on the use of biological assays (e.g., urinary or saliva 
samples) to verify each participant’s drug use and to look at 
whether there is a relationship between AAS use and 
everyday memory deficits, a dose-related study. What 
impact the lifetime dose of AAS might have upon 
everyday memory should also be pursued in future 
research. On a similar note, although the PRMQ has been 
proven to be a valid and reliable measure of everyday RM 
and PM lapses which correlates with objective measure on 
these constructs [24] future research might wish to verify 
these deficits by using objective measures, such as the 
Doors and People test as a measure of RM and the 
Cambridge Prospective Memory Test as a measure of PM. 
Since RM and PM are closely linked to executive 
processes – a collection of processes responsible for 
multiple aspects of cognition, including planning, task 
coordination, impulse control, and attention [36], future 
work might wish to observe what impact persistent AAS 
use has upon all three sets of interrelated cognitive 
processes. Given the roles RM and PM play in everyday life 
and independent living [31] it is important to determine the 
degree to which persistent AAS use might impinge upon 
actual memory performance within a real world memory 
paradigm, since it is the real-world context that is likely to be 
most important to those affected. Finally, although the use 
of AAS is found predominantly in males, its impact on 




 The overall objective of the study was to assess whether 
AAS use was associated with greater deficits in everyday 
RM and PM when compared with a Non-User comparison 
group. The findings support this contention by demonstrating 
significantly more RM and PM deficits in the AAS user 
group. This is the first study to observe an association 
between AAS use and everyday memory deficits, with the 
focus here on RM and PM. The results of our study are of 
relevance to policymakers, health care professionals, 
researchers and AAS user themselves, given that everyday 
memory processes such as RM and PM are seen as critical to 
independent living. For example, failures in recalling 
information from ones past or forgetting to complete future 
actions can seriously compromise everyday function. The 
use of AAS in a non-medical context has become major 
global health issue that requires further research and 
attention. 
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